JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

NCT06226766 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
11
Enrollment
INDUSTRY
Sponsor class

Stopped the decision is based on a strategic realignment of our clinical trial priorities to optimize the overall development pathway for JSKN033

Conditions

Interventions

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd